Bank of New York Mellon
RNA

Bank of New York Mellon’s Atrium Therapeutics RNA Stock Holding History

Bank of New York Mellon’s Portfolio RNA Stock Details RNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$528K Sell
39,252
-4,445
-10% -$58.1K ﹤0.01% 3727
2026
Q1 		$584K Buy
+43,697
New +$614K ﹤0.01% 3524

Other funds holding RNA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
CIEC
Crédit Industriel et Commercial Paris France, France $1.55B AUM 42.08% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
MWM
Moran Wealth Management Naples, Florida $3.67B AUM 36.71% 1-Year Est. Return
FI
Fractal Investments Glastonbury, Connecticut $867M AUM 23.63% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
AA
AlphaCentric Advisors San Juan, Puerto Rico $118M AUM

Bank of New York Mellon's RNA Position: Q2 2026 in Review

Bank of New York Mellon reduced its Atrium Therapeutics (RNA) stake by 10% in Q2 2026, selling an estimated $58.1K and leaving 39,252 shares worth $528K. The position accounts for ﹤0.01% of the portfolio, ranked #3727.

Bank of New York Mellon first reported a position in RNA in Q1 2026 and has held it in 2 quarters since. The position peaked at $584K in Q1 2026. 48 funds tracked by Wall St. Rank hold RNA as of Q2 2026.

  • Bank of New York Mellon held 39,252 shares of Atrium Therapeutics worth $528K as of Q2 2026.
  • Bank of New York Mellon sold 4,445 Atrium Therapeutics shares in Q2 2026, an estimated $58.1K.
  • Atrium Therapeutics made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #3727 holding.
  • Bank of New York Mellon first reported a position in Atrium Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Bank of New York Mellon's Atrium Therapeutics position peaked at $584K in Q1 2026.
  • 48 funds tracked by Wall St. Rank held Atrium Therapeutics as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.